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Morizane et al. (2013) show that donor-matched differentiated derivatives of induced pluripotent stem cells (iPSC) do not cause an
immune response after transplantation, whereas transplantation of HLA-mismatched iPSC derivatives to the same site clearly does.
The importance of these results is discussed in this commentary as we assess how best to move forward with iPSC-based cell therapy.One promise of IPSC-based cell therapy is that personalized
medicine using cells from the patient may be feasible. So-
matic cells could be harvested and reprogrammed with
integration-free methods to produce a stock of clinically
compliant pluripotent cells ready for use at any time in
later life. To ensure that this may really become possible,
various groups have been working on the two major hur-
dles: (1) reduce the cost of development of iPSC and (2)
develop clinical grade processes to generate iPSC lines.
Other groups have approached the problem by suggesting
that, although not fully personalized, one could perhaps
develop HLA-matched banks of lines; indeed, the Japanese
government and others have proposed building a collec-
tion of diverse HLA types that could be then matched be-
tween donor and recipient, akin to the current practice
using bone marrow and tissue transplants (Taylor et al.,
2012; Cyranoski, 2012). Commercial entities have ap-
proached this by offering to develop personalized iPSC
banks, rather like the private cord blood banks that will
store individual samples in anticipation of future need in
‘‘for-profit’’ models (Cave, 2013).
In principle this process seems reasonable; however,
several questions need to be addressed. Perhaps the most
important is whether the cost of making iPSC lines for a
single individual is worth the time and effort or whether
cells matched at the major loci of the histocompatibility
complex may be adequate. Some experiments have even
suggested that mismatched cells may also be an option.
The reverse issue also needs to be considered: it is not un-
reasonable to suppose that autologous iPSC may generate
an immune response because of their exposure to foreign
antigens during the culture period or because of their
expression of embryonic antigens not normally present
in the adult. Likewise, viral agents used for reprogramming
can activate the innate immunity pathway and thus cause
an immune response (Zhao et al., 2011; Guha et al., 2013).
These issues are critical, and adequate experimentalmodels
to assess these issues directly need to be developed. Unam-
biguous answers will dictate where resources and time
should be allocated to develop iPS cell based therapy.
In this issue of Stem Cell Reports,Morizane and colleagues
(Morizane et al., 2013) have developed an elegant system toStem Cell Reports j Vol. 1 j 281–282 j October 1address these issues. They have taken advantage of a pri-
mate colony to generate matched, related, and unmatched
iPSC, which they have then differentiated into dopami-
nergic neurons. These neurons were then transplanted
without immune suppression into the monkey striatum
as autografts or HLA-mismatched allografts to evaluate im-
mune responses (Figure 1). The animals were followed over
a sufficiently long time period to allow examination of
acute, hyperacute, and chronic immune responses. The au-
thors were able to make two important observations:
(1) mismatched cells generated an immune response—
not the acute or hyperacute type of rejection response
seen in mismatched organs but a slow chronic rejection
phenotype mediated by macrophages and T cells; and
(2) no rejection was seen in the matched transplants,
suggesting a clear, albeit small, short-term and larger
long-term benefit of developing matched iPSC lines. Of
importance was the observation that such rejection can
occur even in the brain, which is widely considered as
somewhat immune privileged.
The authors have established a system in which they can
begin to dissect out even more subtle issues related to im-
mune response in a species that is closely related to humans
and has a life span that will allow longer term studies to be
performed. These experiments compliment the elegant
work of Araki et al. (2013), which showed that autologous
or matched ESC and iPSC are equivalent in that they lack
of an immunogenic response when differentiated cell
products are transplanted and provide an opportunity to
perform similar experiments in a primate model. The
same models will also allow us to evaluate which immune
suppressive regime is best in the long run and when and if
any such regime can be discontinued.
Two other advantages of this model system are that we
now have a primate model and corresponding pluripotent
cells from the same species that can be differentiated into
many of the cell types that are being investigated for cell
based treatment. Thus, both human and primate iPSC de-
rivatives can be compared in the same animal species.
This should make it possible to determine whether the
experimental paradigm of the xenograft (human into pri-
mate, human into mouse, human into porcine, etc.) and5, 2013 j ª2013 The Authors 281Open access under CC BY-NC-ND license.
Figure 1. A Schematic Outline of the
Experiment
iPSC were made using viral vectors from
animals that were maintained in a colony.
Differentiation was performed using stan-
dard published protocols and transplants
were placed within the brain.
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predicting what we really want to know: will human
pluripotent stem cell derivatives have therapeutic value
in humans and what will be the requirements for immune
matching or (long-term) immune suppression. Embryonic
stem cell (ESC) lines can be derived from primates, and
were, in fact, derived before human ESC lines (Thomson
et al., 1995), and iPSC could be made from differentiated
derivatives of primate ESC, as has been shown for rodent
and human lines (Teichroeb et al., 2011). One could there-
fore extend these experiments to study subtle differences
between ESC and iPSC cells over a long time period in a
model that is as close to human as is possible.ACKNOWLEDGMENTS
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